Project Overview
The TDB has approved funding to Acrannolife Genomics Private Limited (Chennai) for establishing a high‑tech manufacturing plant at the TANSIDCO Industrial Estate. The plant will produce two home‑grown IVD kits: Trunome GrafAssure for early detection of post‑transplant organ rejection and infection, and TBFYND for rapid tuberculosis diagnosis.
Key Developments
- Financial assistance sanctioned by DST on 17 March 2026.
- Manufacturing facility to be set up in the TANSIDCO Industrial Estate.
- Scale‑up of two proprietary diagnostic kits using cell‑free DNA and LAMP platforms.
- Goal: Reduce dependence on imported diagnostic kits and promote self‑reliance in critical healthcare technologies.
Important Facts
• Trunome GrafAssure is a blood‑based test that detects donor‑derived cell‑free DNA, offering high sensitivity and specificity for early identification of organ rejection or infection, weeks before clinical symptoms appear.
• TBFYND addresses India’s TB burden by delivering a rapid, accurate, and affordable detection method, crucial for timely treatment and containment.
• Both kits are developed in‑house, with secured intellectual property and integrated into the company’s proprietary software for streamlined workflow.
• The project aligns with the Atmanirbhar vision for the health sector.
Exam Relevance
The initiative touches upon several GS paper areas:
- GS 3 – Science & Technology & Health: Role of public funding agencies like TDB/DST in translating research into marketable health technologies.
- GS 1 – Indian Economy: Impact on domestic manufacturing, export potential, and reduction of trade deficit in medical imports.
- GS 2 – Governance: Public‑private partnership model and regulatory aspects of IVD approvals.
- GS 4 – Ethics: Accessibility and affordability of life‑saving diagnostics for vulnerable populations.
Way Forward
To maximise the benefits, aspirants should monitor:
- Implementation of quality‑assurance standards (ISO 13485) for IVD manufacturing.
- Regulatory clearances from the Central Drugs Standard Control Organization (CDSCO) and integration with the National Digital Health Mission.
- Potential for scaling the technology to other infectious diseases and transplant monitoring.
- Collaboration opportunities with research institutes under the BIRAC scheme.
Overall, the TDB‑backed project exemplifies how strategic financial support can foster indigenous innovation, strengthen the health ecosystem, and advance India’s self‑reliance goals.